Dermata Therapeutics, Inc. (DRMA)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Feb 07, 2025

$1.15

P/E Ratio

N/A

Market Cap

$6.16M

Description
Add to research

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.

Metrics
Add to research

Overview

  • HQSan Diego, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerDRMA
  • Price$1.15-5.74%

Trading Information

  • Market cap$6.16M
  • Float30.35%
  • Average Daily Volume (1m)683,197
  • Average Daily Volume (3m)482,264
  • EPS-$21.42

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$3.17M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$3.23M
  • EV-$3.59M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.41
  • Debt/EquityN/A
Documents
Add to research